This is a promotional website intended for UK Healthcare Professionals (HCPs) only.

Prescribing information and adverse event reporting information can be found below.

Log in Place an order
About Products Disease Awareness Supply Resources Events Contact

Signs & symptoms

Chikungunya can cause debilitating symptoms for months or years2,6

Approximately 15–35% of individuals infected with CHIKV are asymptomatic.5

Symptomatic patients will develop symptoms typically 4–8 days after being bitten by an infected mosquito. Symptoms can include fever, severe joint pain, headaches, muscle pain, nausea, fatigue and skin rashes.2 Most symptomatic patients experience acute symptoms which typically resolve in 7–10 days.2,5 However, about 43% of individuals* infected are affected chronically and may experience debilitating joint paint that can last from months to years.2,6 Up to 78.6% of cases may have persistent muscle and joint symptoms.†13

*Based on a systematic review and meta-analysis study that included 6532 chikungunya patients.

†Based on a survey conducted in Mauritius in 2008 that included 173 individuals identified with chikungunya. Persistent symptoms were present 27.5 months after infection.

Chikungunya has no cure2

While symptoms can be treated, there are currently no specific antiviral drug treatments available for CHIKV infections.2

Treatment for acute symptoms of chikungunya can include rest, fluids and use of analgesics and anti-pyretics.2

View Prescribing InformationFurther information on SMPC Further information on PIL

Place an order

Useful links

For healthcare professionals:

UK Health Security Agency TravelHealthPro World Health Organization U.S. Centers for Disease Control and Prevention

To recommend to travellers:

TravelHealthPro GOV.UK Foreign travel advice

References

  1. World Health Organization. Global Chikungunya Epidemiology Update. June 2025. Available at: https://cdn.who.int/media/docs/default-source/documents/epp/ezh/chikungunya-epidemiology-update_11june2025.pdf?sfvrsn=ffddcf60_4&download=true. Accessed: June 2025.
  2. World Health Organization. Chikungunya factsheet. April 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/chikungunya. Accessed: June 2025.
  3. Ryan SJ, Carlson CJ, Mordecai EA, Johnson LR. Global expansion and redistribution of Aedes-borne virus transmission risk with climate change. PLoS Negl Trop Dis. 2019;13(3):e0007213.
  4. Tjaden NB, Cheng Y, Beierkuhnlein C, Thomas SM. Chikungunya beyond the tropics: Where and when do we expect disease transmission in Europe? Viruses. 2021;13(6):1024.
  5. Centers for Disease Control and Prevention. Chikungunya. CDC Yellow Book 2026. April 2025. Available at: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/chikungunya.html. Accessed: June 2025.
  6. Paixão ES, Rodrigues LC, Costa M da CN, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;112(7):301-316.
  7. IXCHIQ. Summary of Product Characteristics. March 2025. Available at: https://www.medicines.org.uk/emc/product/100652/smpc. Accessed: June 2025.
  8. Zurbia-Flores GM, Reyes-Sandoval A, Kim YC. Chikungunya virus: Priority pathogen or passing trend? Vaccines (Basel). 2023;11(3):568.
  9. European Centre for Disease Prevention and Control. Chikungunya virus disease – Annual Epidemiological Report for 2022. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/CHIK_AER_2022_report.pdf.
  10. Rezza G, Nicoletti L, Angelini R, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840-1846.
  11. UK Health Security Agency. Travel-associated infections in England, Wales and Northern Ireland: 2024. March 2025. Available at: https://www.gov.uk/government/publications/travel-associated-infections/travel-associated-infections-in-england-wales-and-northern-ireland-2024. Accessed: June 2025.
  12. Micheleto JPC, Melo KA, Veloso FCS, Kassar SB, Oliveira MJC. Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Tropical Medicine & International Health. 2025;30(4):235-245.
  13. Essackjee K, Goorah S, Ramchurn SK, Cheeneebash J, Walker-Bone K. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440-447.
  14. NHS Scotland. Mosquito Bite Avoidance - Fit for Travel. Available at: https://www.fitfortravel.nhs.uk/advice/malaria/mosquito-bite-avoidance. Accessed: June 2025.
  15. Britannica. Aedes | Description, Life Cycle, & Disease Transmission. April 2025. Available at: https://www.britannica.com/animal/Aedes. Accessed: June 2025.
  16. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138-2147.

Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to the Valneva UK Ltd Medical Information department on Tel: 01506 446608 or via email: safety@valneva.com

2026 - Please use a modern browser